



We now offer Feline Interleukin-2 Immunotherapy

Contents & Doses
3 x 1 Dose (1 mL), Lyophilized
0.1 x 1 mL, Single Dose

Store at 2-8°C (35-46°F)
For veterinary use only

Notice: Product license
is conditional, efficacy
studies are in progress.

08/21/08/03

Feline Interleukin-2 Immunomodulator
Live Canarypox Vector



6 doses

Manufactured by
Merial, Inc.
Atlanta, GA 30316 USA
U.S. Pat. Lic. No. 599
1-800-828-6121 (1-800-828-6121)

Product No. T2386



Feline Interleukin-2
Vaccine

Live Canarypox Vector

Notice: Product license is conditional
efficacy studies are in progress.

MERIAL

Feline Interleukin-2 Immunotherapy is recommended to delay post-surgical recurrence of feline fibrosarcomas in adult cats with stage 1 disease.

- Both a proof of concept study using a similar immunotherapy and an internal study that utilized Feline Interleukin-2 Immunomodulator demonstrated an extension in the time to recurrence of feline fibrosarcomas following surgical removal and radiotherapy.^{1,2}
- Feline Interleukin-2 Immunomodulator therapy consists of 6 treatments. The first treatment is given 1 week prior to surgical excision of the fibrosarcoma. The second treatment is given 1 week after surgical excision, followed by 3 treatments at one week intervals, then we wait two weeks for the sixth and final treatment.

We encourage you to refer fibrosarcoma patients to us so that we can consider them for this therapy. If you have questions about Feline Interleukin-2 Immunomodulator, please feel free to contact Merial's Technical Solutions at **1-888-MERIAL-1, option 1, then option 4.**

NOTICE: The USDA has issued a conditional U.S. Veterinary Biological Product License for this therapeutic vaccine. This conditional license is based upon USDA requirements for demonstration of safety and a reasonable expectation of efficacy. Additional potency and efficacy test studies are in progress.

¹ Jourdir JM, Moste C, Bonnet MC, et al. Local immunotherapy of spontaneous feline fibrosarcomas using recombinant poxviruses expressing interleukin 2 (IL2). *Gene Therapy*. 2003;10(26):2126-2132.

² Data on file at Merial.